MARKET

IPA

IPA

Immunoprecise
NASDAQ

Real-time Quotes | Nasdaq Last Sale

3.960
-0.030
-0.75%
Opening 12:39 06/29 EDT
OPEN
3.940
PREV CLOSE
3.990
HIGH
4.040
LOW
3.940
VOLUME
329
TURNOVER
1.27K
52 WEEK HIGH
16.47
52 WEEK LOW
3.510
MARKET CAP
93.21M
P/E (TTM)
-5.6491
1D
5D
1M
3M
1Y
5Y
Despite currently being unprofitable, ImmunoPrecise Antibodies (CVE:IPA) has delivered a 44% return to shareholders over 3 years
ImmunoPrecise Antibodies Ltd. ( CVE:IPA ) shareholders have seen the share price descend 18% over the month. But that...
Simply Wall St. · 4d ago
IPA's Subsidiary BioStrand Secures Second VLAIO Research Grant
Diepe IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the “Company” or “IPA”) (NASDAQ:IPA) (TSXV:IPA) is pleased to share that IPA’s subsidiary Biostrand, a Belgian end-to-end multi-omics analysis
Benzinga · 05/09 12:22
ImmunoPrecise antibody cocktail shows neutralizing activity versus Omicron BA.2 in lab test
ImmunoPrecise Antibodies (NASDAQ:IPA) said its antibody cocktail PolyTope TATX-03 showed strong neutralizing activity against Omicron subvariant BA.2 in lab test. In-vitro data showed that the BA.2 pseudovirus was neutralized with a
Seekingalpha · 04/20 13:06
BRIEF-IPA Says Data On PolyTope TATX-03 Antibody Cocktail Shows Neutralizing Activity Toward Omicron BA.2
reuters.com · 04/20 12:25
WWR, CTXR and OTIC among pre market gainers
Clarus Therapeutics (CRXT) +18%. AlloVir (ALVR) +18% on FDA regenerative medicine tag for posoleucel to prevent 6 viruses in cell transplant patients. Westwater Resources (WWR) +15%  and Alabama Graphite Products break ground on
Seekingalpha · 04/20 12:19
ImmunoPrecise Antibodies Shares Spike Higher; Says Co's Advanced PolyTope TATX-03, a Multi-Antibody Cocktail, Potently Prevents In Vitro Infection Of Cells By Currently Dominant Omicron Sublineage BA.2, In Addition To All Other Variants Of Concern
IPA's Advanced PolyTope® TATX-03, a Multi-Antibody Cocktail, Potently Prevents In Vitro Infection of Cells by the Currently Dominant Omicron Sublineage BA.2, in Addition to all Other Variants of
Benzinga · 04/20 12:03
IPA’s Advanced PolyTope® TATX-03, a Multi-Antibody Cocktail, Potently Prevents In Vitro Infection of Cells by the Currently Dominant Omicron Sublineage BA.2, in Addition to all Other Variants of Concern
VICTORIA, British Columbia, April 20, 2022--IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the "Company" or "IPA") (NASDAQ: IPA) (TSXV: IPA) is pleased to share the outcome of recent laboratory data on their PolyTope® TATX-03 antibody cocktail, which demonstrates st...
Business Wire · 04/20 12:01
IPA Completes Acquisition of Belgian Technology Companies BioStrand, BioKey, and BioClue – Adding Artificial Intelligence-Driven Analytics to its Antibody Discovery Capabilities and Offerings
VICTORIA, British Columbia, April 14, 2022--IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the "Company" or "IPA") (NASDAQ: IPA) (TSXV: IPA) is pleased to announce that it has completed its previously announced acquisition of control over BioStrand BV, BioKey BV, an...
Business Wire · 04/14 12:01
More
No Data
Learn about the latest financial forecast of IPA. Analyze the recent business situations of Immunoprecise through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 1 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

0.00%Strong Buy
100.00%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average IPA stock price target is 12.07 with a high estimate of 12.07 and a low estimate of 12.07.
High12.07
Average12.07
Low12.07
Current 3.960
EPS
Actual
Estimate
-0.18-0.13-0.09-0.04
Q4 2021
Q1 2022
Q2 2022
Q3 2022
Q4 2022
Institutional Holdings
Institutions: 18
Institutional Holdings: 1.34M
% Owned: 5.40%
Shares Outstanding: 23.54M
TypeInstitutionsShares
Increased
4
224.42K
New
3
20.33K
Decreased
4
68.08K
Sold Out
7
212.04K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
+0.62%
Pharmaceuticals & Medical Research
+0.53%
Key Executives
Non-Executive Chairman/Independent Director
James Kuo
President/Chief Executive Officer/Director
Jennifer Bath
Chief Financial Officer
Lisa Helbling
Chief Scientific Officer
Ilse Roodink
Vice President
Kari Graber
Other
Stefan Lang
Independent Director
Paul Andreola
Independent Director
Robert Burke
Independent Director
Gregory Smith
No Data
No Data
About IPA
ImmunoPrecise Antibodies Ltd. is a technology platform company that is engaged in the full-service therapeutic antibody discovery. The Company is focused on offering species-agnostic advancements, such as the B cell Select single-cell interrogation technology, DeepDisplay custom phage libraries, as well as the Abthena bispecific program. Its geographical segments include United States of America, Canada and Europe. The Company’s Antibody Discovery offers design, immunization, characterization and optimization, and preclinical services. The Company offers mammalian protein expression and purification services as stand-alone or in combination after an antibody discovery project to produce the number of antibodies that need for further work. Its mammalian rPEx platform allows the production of all kinds of proteins, including difficult-to-express proteins, Fc-fusion proteins and bispecific antibodies.

Webull offers kinds of Immunoprecise Antibodies Ltd stock information, including NASDAQ:IPA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, IPA stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading IPA stock methods without spending real money on the virtual paper trading platform.